Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $17

Benzinga Newsdesk www.benzinga.com Neutral 54.7%

Neg 0% Neu 54.7% Pos 0%

Rodman & Renshaw analyst Michael King initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $17.